An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

A wide inter-individual variability in the therapeutic response to cyclin-dependent kinases 4 and 6 inhibitors (CDKis) has been reported. We herein present a case series of five patients treated with either palbociclib or ribociclib referred to our clinical pharmacological counselling, including the...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Rossana Roncato, Lorenzo Gerratana, Lorenza Palmero, Sara Gagno, Ariana Soledad Poetto, Elena Peruzzi, Martina Zanchetta, Bianca Posocco, Elena De Mattia, Giovanni Canil, Martina Alberti, Marco Orleni, Giuseppe Toffoli, Fabio Puglisi, Erika Cecchin
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-07-01
Saila:	Frontiers in Pharmacology
Gaiak:	personalized medicine TDM polymorphisms pharmacological counselling breast cancer CDK4/6 inhibitors
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fphar.2022.897951/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!